Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Andrology

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 23 articles: HTML format

Single Articles

July 2020
1. CALLEC L, Lardy-Cleaud A, Guerrini-Rousseau L, Alapetite C, et al
   Relapsing intracranial germ cell tumours warrant retreatment.
   Eur J Cancer. 2020;136:186-194.
   PubMed     Abstract available
   
   
   May 2020
2. CHOI MC, Chung YS, Lee JW, Kwon BS, et al
   Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R).
   Eur J Cancer. 2020;133:56-65.
   PubMed     Abstract available
   
   
   April 2020
3. SEIDEL C, Daugaard G, Nestler T, Tryakin A, et al
   Human chorionic gonadotropin-positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3).
   Eur J Cancer. 2020;132:127-135.
   PubMed     Abstract available
   
   
   March 2020
4. BERNEY DM, Shamash J, Stoneham S, Lockley M, et al
   Response to: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
   Eur J Cancer. 2020 Mar 18. pii: S0959-8049(20)30048.
   PubMed    
   
   
   
5. PASHANKAR F, Frazier AL
   Re: A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
   Eur J Cancer. 2020 Mar 13. pii: S0959-8049(20)30047.
   PubMed    
   
   
   
6. GILBERT A, Drinkwater K, McParland L, Adams R, et al
   UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomes.
   Eur J Cancer. 2020;128:7-16.
   PubMed     Abstract available
   
   
   January 2020
7. CAFFERTY FH, White JD, Shamash J, Hennig I, et al
   Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II
   Eur J Cancer. 2020;127:139-149.
   PubMed     Abstract available
   
   
   July 2019
8. DEPANI S, Stoneham S, Krailo M, Xia C, et al
   Results from the UK Children's Cancer and Leukaemia Group study of extracranial germ cell tumours in children and adolescents (GCIII).
   Eur J Cancer. 2019;118:49-57.
   PubMed     Abstract available
   
   
   April 2019
9. NEWTON C, Murali K, Ahmad A, Hockings H, et al
   A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
   Eur J Cancer. 2019;113:19-27.
   PubMed     Abstract available
   
   
   May 2018
10. FRAZIER AL, Stoneham S, Rodriguez-Galindo C, Dang H, et al
    Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: A report of the Malignant Germ Cell International Consortium.
    Eur J Cancer. 2018;98:30-37.
    PubMed     Abstract available
    
    
    April 2018
11. MOKE DJ, Thomas SM, Hiemenz MC, Nael A, et al
    Three synchronous malignancies in a patient with DICER1 syndrome.
    Eur J Cancer. 2018;93:140-143.
    PubMed    
    
    
    March 2018
12. ALIFRANGIS C, Wilson P, Shamash J
    Letter to the Editor: Central nervous system relapse rate and dose intensification in poor risk metastatic germ cell tumours-A comment on: 'Patterns of relapse in poor prognosis germ cell tumours in the GETUG-13 trial: Implications for the assessment
    Eur J Cancer. 2018 Mar 31. pii: S0959-8049(18)30226.
    PubMed    
    
    
    
13. FRESNEAU B, Orbach D, Faure-Conter C, Sudour-Bonnange H, et al
    Is alpha-fetoprotein decline a prognostic factor of childhood non-seminomatous germ cell tumours? Results of the French TGM95 study.
    Eur J Cancer. 2018;95:11-19.
    PubMed     Abstract available
    
    
    
14. SEIDEL C, Daugaard G, Tryakin A, Necchi A, et al
    Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors.
    Eur J Cancer. 2018;94:16-25.
    PubMed     Abstract available
    
    
    
15. ABIUSO AMB, Varela ML, Haro Durand L, Besio Moreno M, et al
    Histamine H4 receptor as a novel therapeutic target for the treatment of Leydig-cell tumours in prepubertal boys.
    Eur J Cancer. 2018;91:125-135.
    PubMed     Abstract available
    
    
    January 2018
16. DUHIL DE BENAZE G, Pacquement H, Faure-Conter C, Patte C, et al
    Paediatric dysgerminoma: Results of three consecutive French germ cell tumours clinical studies (TGM-85/90/95) with late effects study.
    Eur J Cancer. 2018;91:30-37.
    PubMed     Abstract available
    
    
    November 2017
17. LORIOT Y, Pagliaro L, Flechon A, Mardiak J, et al
    Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.
    Eur J Cancer. 2017;87:140-146.
    PubMed     Abstract available
    
    
    October 2017
18. DE LA PENA H, Sharma A, Glicksman C, Joseph J, et al
    No longer any role for routine follow-up chest x-rays in men with stage I germ cell cancer.
    Eur J Cancer. 2017;84:354-359.
    PubMed     Abstract available
    
    
    
19. VERMEULEN RFM, Beurden MV, Kieffer JM, Bleiker EMA, et al
    Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study.
    Eur J Cancer. 2017;84:159-167.
    PubMed     Abstract available
    
    
    July 2017
20. BANDAK M, Jorgensen N, Juul A, Lauritsen J, et al
    Leydig cell dysfunction, systemic inflammation and metabolic syndrome in long-term testicular cancer survivors.
    Eur J Cancer. 2017;84:9-17.
    PubMed     Abstract available
    
    
    May 2017
21. ZSCHABITZ S, Lasitschka F, Hadaschik B, Hofheinz RD, et al
    Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
    Eur J Cancer. 2017;76:1-7.
    PubMed     Abstract available
    
    
    March 2017
22. GIZZI M, Oberic L, Massard C, Poterie A, et al
    Corrigendum to "Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours" [Eur J Cancer 69 (2016) 151-157].
    Eur J Cancer. 2017 Mar 7. pii: S0959-8049(17)30740.
    PubMed    
    
    
    November 2016
23. GIZZI M, Oberic L, Massard C, Poterie A, et al
    Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours.
    Eur J Cancer. 2016;69:151-157.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Andrology is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: